Cancer Epidemiology Biomarkers & Prevention, Vol 2, Issue 3 243-247, Copyright © 1993 by American Association for Cancer Research

ARTICLES

Evaluation of alpha-difluoromethylornithine as a potential chemopreventive agent: tolerance to daily oral administration in humans

PJ Creaven, L Pendyala and NJ Petrelli
Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263.

An initial clinical trial of alpha-difluoromethylornithine given p.o. daily for 6 months was carried out in 27 subjects free of disease following surgery for malignancy or in a defined high-risk group for cancer. The aim was to determine the highest nontoxic dose, principal side effects, and pharmacokinetic parameters. The starting dose was 200 mg/m2/day in divided doses with escalation each month in the absence of toxicity to 6400 mg/m2/day or to the highest nontoxic dose, whichever was lower. When the highest nontoxic dose was reached, this dose was continued to complete 26 weeks of treatment. Twenty-two subjects completed 26 weeks of alpha-difluoromethylornithine treatment of whom 20 reached a nontoxic dose of at least 1600 mg/m2/day. The dose-limiting toxicity was loss of high-tone auditory acuity on an audiogram. Other side effects included diarrhea, fatigue, joint pain, insomnia, and rash. Pharmacokinetics were linear with dose. Area under the plasma concentration x time curve and maximum plasma concentration of alpha-difluoromethylornithine did not predict for development of ototoxicity. The dose for phase II chemoprevention studies should not exceed 1600 mg/m2/day.

This article has been cited by other articles:

				C. D. Lao, P. Backoff, L. I. Shotland, D. McCarty, T. Eaton, F. G. Ondrey, J. L. Viner, S. J. Spechler, E. T. Hawk, and D. E. Brenner Irreversible Ototoxicity Associated with Difluoromethylornithine Cancer Epidemiol. Biomarkers Prev., July 1, 2004; 13(7): 1250 - 1252. [Abstract] [Full Text] [PDF]

				C. J. Fabian, B. F. Kimler, D. A. Brady, M. S. Mayo, C. H. J. Chang, J. A. Ferraro, C. M. Zalles, A. L. Stanton, S. Masood, W. E. Grizzle, et al. A Phase II Breast Cancer Chemoprevention Trial of Oral {alpha}-Difluoromethylornithine: Breast Tissue, Imaging, and Serum and Urine Biomarkers Clin. Cancer Res., October 1, 2002; 8(10): 3105 - 3117. [Abstract] [Full Text] [PDF]

				L. I. Shotland, F. G. Ondrey, K. A. Mayo, and J. L. Viner Recommendations for Cancer Prevention Trials Using Potentially Ototoxic Test Agents J. Clin. Oncol., March 15, 2001; 19(6): 1658 - 1663. [Abstract] [Full Text] [PDF]

				D. S. Alberts, R. T. Dorr, J. G. Einspahr, M. Aickin, K. Saboda, M. J. Xu, Y.-M. Peng, R. Goldman, J. A. Foote, J. A. Warneke, et al. Chemoprevention of Human Actinic Keratoses by Topical 2-(Difluoromethyl)-dl-ornithine Cancer Epidemiol. Biomarkers Prev., December 1, 2000; 9(12): 1281 - 1286. [Abstract] [Full Text]

				P. P. Carbone, J. A. Douglas, J. Thomas, K. Tutsch, M. Pomplun, M. Hamielec, and D. Pauk Bioavailability Study of Oral Liquid and Tablet Forms of {{alpha}}-Difluoromethylornithine Clin. Cancer Res., October 1, 2000; 6(10): 3850 - 3854. [Abstract] [Full Text]

				L. Alhonen, M. Pietilä, M. Halmekytö, D. L. Kramer, J. Jänne, and C. W. Porter Transgenic Mice with Activated Polyamine Catabolism due to Overexpression of Spermidine/Spermine N1-Acetyltransferase Show Enhanced Sensitivity to the Polyamine Analog, N1,N11-Diethylnorspermine Mol. Pharmacol., April 1, 1999; 55(4): 693 - 698. [Abstract] [Full Text]